Unlike other ACE inhibitors that are primarily excreted by the kidneys,<unk>  is eliminated from the body by both renal and hepatic pathways. This characteristic of<unk>  makes the drug a safer choice than other ACE inhibitors for heart failure patients with impaired kidney function resulting from poor perfusion as<unk>  can still be eliminated by the liver, preventing accumulation of the drug in the body.<unk>  is de-esterified by the liver or gastrointestinal mucosa and is converted to its active form,<unk> at.<unk> at competitively binds to ACE, preventing ACE from binding to and converting angiotensin I to angiotensin II. Inhibiting the production of AII lowers peripheral vascular resistance, decreases afterload, and decreases blood pressure, thus helping to alleviate the negative effects of AII on cardiac performance.
Fosinopril
Captopril
Lisinopril
Nebivolol
Azilsartan
Hydralazine
Telmisartan
Perindopril